Cysteine in carbon metabolism reprogramming Metabolic reprogramming, an important cancer hallmark, refers to the ability of cancer cells to modify their metabolism, to support the increased energy demand due to the continuous growth and rapid proliferation of cancerous cells
It determines: Drug clearance Half-life Steady-state concentration In other words: First-pass metabolism How much drug enters circulation Systemic metabolism How long and how effectively it acts Understanding this distinction is essential for: Dose adjustment Therapeutic drug monitoring Managing drug interactions Treating patients with liver disease This is where pharmacokinetics becomes real clinical decision-making
van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri MNS, Mares NWG, Mahmmod N, van Asseldonk DP, Lutgens MDMW, Kuyvenhoven JP, Rietdijk ST, Nissen CLH, Koehestanie P, de Boer HNK, de Jonge R, Bouma G, Bulatovi alasan M, van Schaik F, van der Horst I, Meiland R, Franois-Verweij M, Sijbring A, Zoutendijk R, Al-toma A, Boerlage T, van Wenum M, van der Schaar P, van Zanden MEP, Bierens-Peters DDA, Lubsen M, Meinsma-Span L, Seinen ML, Jansen J, Scholten P, de Schrijver A, Rmkens T, van Hee K, ter Haar-Sive droste J, Rijsdijk E, van Boxtel K, Tielemans GBM (2023) Therapeutic drug monitoring of methotrexate in patients with Crohns disease
As an agonist of the growth hormone secretagogue receptor (GHS-R)the same receptor targeted by ghrelin, often referred to as the ghrelin receptorit stimulates the release of GH from the anterior pituitary gland
Zhang, G., et al
